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Due to the risks of disease progression and transmission to the newborn, treatment of tuberculosis is often pursued during
pregnancy and ﬁxed-dose combined antituberculous agents have been found to be beneﬁcial. Unfortunately, there is paucity of
data on the safety of the ﬁxed-dose combined antituberculous drugs during pregnancy. This study intends to assess the teratogenic
eﬀect of ﬁxed-dose combined antituberculous drugs on the organogenesis stage of fetal development and also investigate the
possible roles of vitamin C in modulating the teratogenic eﬀects of these agents on the fetus using animal model. Pregnant
rats were divided into 3 groups with 12 animals per group: group 1 received distilled water (10mL/kg) orally; group 2 received
51.4mg/kg/day of ﬁxed-dose combined antituberculous agents orally; group 3 received 51.4mg/kg/day of ﬁxed-dose combined
antituberculous agents plus vitamin C (10mg/kg/day) orally. Six rats in each group were randomly selected and sacriﬁced on day
20 by cervical dislocation prior to day 21 of gestation, and the foetuses were harvested through abdominal incision for physical
examination. Blood samples were collected from the 1st ﬁlial rats of the remaining six animals for biochemical and hematological
examination. The liver, kidney, heart, and brain of all the sacriﬁced animals were used for histopathological examination.
There were signiﬁcant (P ≤ 0.05) low birth weights of the foetuses of the animals that were treated with ﬁxed-dose combined
antituberculous agents. The haematological parameters also revealed a reduction in the platelets counts and neutrophiles at the
ﬁrst ﬁlial generation. Signiﬁcant (P ≤ 0.05) elevations in the levels of aspartate aminotransferase (AST) and alkaline phosphatase
(ALP) in the foetuses of the animals treated with ﬁxed-dose combined antituberculous agents were also observed. However, the
combination of vitamin C with ﬁxed-dose combined antituberculous agents signiﬁcantly (P ≤ 0.05) reduced the level of AST.
Fixed-dose combined antituberculous agents have teratogenic potential as shown in low birth weight and mild liver damage in
the ﬁrst ﬁlial of the treated animals. As much as it is imminent to treat TB patients in pregnancy, there is need to always exercise
caution and clinically weigh the risk-beneﬁt ratio.
“This paper is dedicated to the late memory of the beloved wife of Olufunsho Awodele (Mrs Deborah Funmilola Awodele)
who died at childbirth on 1st January, 2012. Funmilola made remarkable contributions in the ﬁeld of nursing sciences
especially maternal and child health. Tribute to an intelligent woman.”
1.Introduction
Tuberculosis (TB) is the world’s greatest infectious killer of
women of reproductive age and the leading cause of death
among people with HIV/AIDS. Untreated tuberculosis,
however, has been associated with higher morbidity and
mortality among pregnant women [1]. In 2007, an estimated
13.7 million people had active TB disease, with 9.3 million
new cases and 1.8 million deaths. The annual incidence rate
varied from 363 per 100,000 in Africa to 32 per 100,000 in
the Americas [2].
Maternal tuberculosis has been associated with an in-2 The Scientiﬁc World Journal
creased risk of spontaneous abortion, perinatal mortality,
a n dl o wb i r t hw e i g h ti ns o m es t u d i e s[ 3]. Due to the risks
of disease progression and transmission to the newborn,
treatment of tuberculosis is often pursued during pregnancy
[4, 5]. Almost all authors recommend some forms of aggres-
sive treatment of active tuberculosis, given that the beneﬁts
of treatment likely outweigh the risk of fetal damage, even
in the case of drugs that may have some toxicity associated
with in utero exposure [6]. One of the major problems mili-
tating against the management of tuberculosis is the lack of
compliance to medication by the infected patients as a result
of multidrug needed to be taken daily leading to resistance
[7]. Thus, the World Health Organization (WHO) and the
International Union against Tuberculosis and Lung Disease
(IUATLD) recommend the replacement of single-drug pre-
parations by ﬁxed-dose combination therapy (FDCs) [8].
The justiﬁcation for this recommendation is that FDCs pro-
vide a simple approach to delivering the correct number of
drugs at the correct dosage as all the necessary drugs are
combined in a single tablet [9]. Combinations of two to four
anti-TB drugs administered in ﬁxed doses in a single tablet
decrease the risk of developing multidrug-resistant tubercul-
osis[10],andﬁxed-dosedrugcombinationshavebeenfound
to be beneﬁcial and cost-eﬀective treatment for TB [11].
Quoting data from the old literature, the use of ethiona-
mide and prothionamide during pregnancy remains contro-
versial.Inrodents,highdosesofethionamidehavebeenasso-
ciated with growth retardation, abortions, and malforma-
tions, including CNS defects [12]. In human studies, 2
reportsreviewing47casesfailedtoobservedeleteriouseﬀects
of ethionamide [13]. On the other hand, Potworowska et al.
[14] encountered congenital malformations in 7 of 23 chil-
dren exposed to ethionamide. The work of Schardein [15],
with approximately 70 case reports, found no teratogenic
eﬀectswiththesedrugs.Manyauthorsstillrecommendwith-
holding their use in pregnancy [16], although some recog-
nize the need to use these drugs if the risk of active disease
outweighs potential risks to the fetus [3].
Anumberoftheoreticalmechanismshavesuggestedpot-
ential modiﬁcation of fetal toxicity (as seen in combination
therapies) to include the induction of biochemical or meta-
bolic changes (with negative consequences on the fetus) in
the maternal system that would not have arisen in the use of
asingledrugorthecombinationincreasingthedoseavailable
tointeractwithfetalmechanismleadingtonegativeeﬀectsor
changes that are absent in the use of the drug singly. An im-
portant mechanism of induction of fetal toxicity by terato-
genic agents is the induction of oxidative stress in the fetal
system [17]. Oxidative stress can cause cell death, and even
moderateoxidationcantriggerapoptosis,whilemoreintense
stresses may cause necrosis [18].
Inferringfromtheabovefacts,itsuﬃcestosaythereislit-
tle and inconsistent data on the safety of the ﬁxed-dose com-
bined antituberculous drugs during pregnancy. Therefore,
thisstudyintendstoassesstheteratogeniceﬀectofﬁxed-dose
combined antituberculous drugs on the organogenesis stage
of fetal development and also investigate the possible roles
of vitamin C (an antioxidant) in modulating the teratogenic
eﬀects of these agents on the fetus using animal model. The
ﬁndings obtained from this study may give a directional
surveillance in humans and possible generation of more reli-
able and consistent data.
2.Methodology
2.1. Drugs. Fixed-dose combined antituberculous (TB)
agentscontainrifampicin150mg,isoniazid75mg,pyrazina-
mide 400mg and Ethambutol 275mg per caplet. The ﬁxed-
dose combination drugs were obtained from Direct Obser-
ved Treatment (DOT) Clinic in Lagos University Teaching
Hospital, Lagos-Nigeria. Ascorbic acid (Vitamin C Tablets
(100mg per tablet)) was obtained from the outpatient Phar-
macy Department of the Lagos University Teaching Hospital,
Lagos-Nigeria.
2.2. Animals. Sexually mature adult Albino rats (male and
female) with average weight of 160g were obtained from the
LaboratoryAnimalCentreofCollegeofMedicine,University
ofLagos,Nigeria.TheanimalswereauthenticatedinZoology
Department, Faculty of Science, University of Lagos, Nigeria.
Theyweremadetoacclimatizefortwoweeksbeforethecom-
mencement of the experiment. The animals were fed on
Pﬁzer Animal Feed cubes and water ad libitum. The investi-
gation conforms to the Guide for the Care and Use of Labo-
ratory Animals published by the U. S. National Institutes of
Health(NIHPublicationNo.85-23,revised1996)forstudies
involving experimental animals. Ethical permission for use
of animals for this research was obtained from the College of
Medicine, University of Lagos, Research Ethics Committee.
2.3.CycleDetermination. Aftertwoweeksofacclimatization,
vaginalsmearsoffemaleratsweredoneforviewingunderthe
microscope to determine the females that will be receptive
to the males during mating. Vaginal secretion was collected
(in the morning between 8:00 and 9:00 a.m.) with a plastic
pipette ﬁlled with 10μL of normal saline by inserting the tip
into the rat vagina, but not deeply. Vaginal ﬂuid was then
placed on glass slides to observe under a light microscope
(×10 magniﬁcation) according to the method of Marcondes
et al. [19]. The proestrus stage is the receptive state that was
microscopicallychecked outfor[20],andthevirginalsmears
of mated female rats were assessed for the presence of sperm
plug. The ﬁrst day to see sperm plug was taken as day 1 of
pregnancy.
2.4. Treatment Groups. Rats have average gestational period
of 21 days. Pregnant rats were divided into 3 groups with 12
animals per group. The therapeutic doses of drugs were ad-
ministered to simulate the treatment pattern in DOT Clinic
of the University of Lagos Teaching Hospital (LUTH), Lagos,
Nigeria
Group 1 received distilled water (10mL/kg) orally.
Group 2 received 51.4mg/kg/day of ﬁxed dose com-
bined antituberculous agents orally.The Scientiﬁc World Journal 3
Table 1: Incidence of resorption and live foetus in treated rats.
Groups Stage of drug
exposure
Percentage (%) of live
foetus
Average number of live
foetus
Number of
resorption
Group 1 Organogenesis 100 7.33 ±0.023 0
Group 2 Organogenesis 100 8.33 ±0.43 0
Group 3 Organogenesis 100 8.00 ±0.00 0
Group 1: control group. Group 2: administered with clinical dose (51.4mg/kg/day) of ﬁxed-dose combined antituberculous agents. Group 3: administered
with clinical dose of ﬁxed-dose combined antituberculous agents plus 10mg/kg/day of Vitamin C.
Table 2: Incidence of growth retardation and size abnormality in fetuses of treated rats.
Groups SE BW + PW (g)
(Mean ± SEM)
BW (g)
(Mean± SEM)
PW (g)
(Mean±SEM)
CRL (cm)
(Mean ± SEM)
UCL (cm)
(Mean ± SEM)
TL (CM)
(Mean ± SEM)
Group 1 OR 4.793 ±0.6750 4.173 ± 0.6165 0.6205 ±0.01799 4.583 ±0.1222 2.967 ±0.1453 1.267±0.04216
Group 2 OR 4.181 ±0.1340
∗ 3.567 ±0.06215
∗ 0.4818 ±0.01337
∗ 4.733±0.09189 2.883 ±0.1621 1.200±0.05164
Group 3 OR 3.638 ±0.233
∗ 3.075 ±0.1341
∗ 0.6233 ±0.03565
∗ 4.183 ±0.2469 2.800 ±0.1317 1.117±0.05426
SE: stage of exposure, OR: organogenesis, BW + PW: body weight + placenta weight, BW: body weight, PW: placenta weight, CRL: crown-rump length, UCL:
umbilical cord length, TL: tail length.
∗P ≤ 0.05 compared with group 1 (control).
Group 1: control group. Group 2: administered with clinical dose (51.4mg/kg/day) of ﬁxed-dose combined antituberculous agents. Group 3: administered
with clinical dose of ﬁxed-dose combined antituberculous agents plus 10mg/kg/day of Vitamin C.
Group 3 received 51.4mg/kg/day of ﬁxed dose
combined antituberculous agents plus vitamin C
(10mg/kg/day) orally.
2.5. Morphological and Histopathological Examination. Six
rats in each group were randomly selected, subjected to light
ether anesthesia, and sacriﬁced on day 20 by cervical disloca-
tion prior to day 21 of gestation, and the foetuses were har-
vested through abdominal incision for physical examination.
The tail length, crown-rump length, umbilical cord length,
total weight (includes weight of fetus and placenta), and
weights of fetus were recorded. After the physical examina-
tion, the harvested foetuses were taken for gross histopatho-
logical analysis at the Morbid Anatomy Department of the
College of Medicine, University of Lagos. The histopatholog-
ical features observed were formation of digital rays, neural
tube defects, cleft palate, and general growth abnormalities.
2.6. Biochemical and Haematological Examination. The six
other rats in each group were allowed to litter, and the litters
w e r ea l l o w e dt og r o wf o rap e r i o do fa tl e a s to n em o n t h
after which six animals from each litter were randomly
selected. Blood samples were collected from the animals for
biochemical and hematological examination. The fully auto-
mated clinical chemistry analyzer (Hitachi 912, Boehringer
Mannheim, Germany) was used to determine the levels of
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphatase (ALP), urea, creatinine, total
protein,cholesterol,andtriglyceride;fullyautomatedclinical
haematological analyzer (Pentra-XL 80, Horiba ABX, USA)
was also used to determine the levels of white blood cells, red
blood cells, hemoglobin, hematocrit (packed cell volume),
platelet, lymphocyte count, and percentage neutrophiles.
2.7. Histopathological Examination. The liver, kidney, heart,
and brain of all the sacriﬁced animals were ﬁxed in 10%
formalin in labeled bottles. Tissues were processed routinely
andembedded inparaﬃn wax.Sectionsof 5μthickness were
cut, stained with haematoxylin and eosin, and examined
under the light microscope by a pathologist.
2.8. Statistical Analysis. Results were expressed as mean ±
S E M .T h ed a t aw e r es u b j e c t e dt oo n e - w a ya n a l y s i so f
variance (ANOVA) test, and diﬀerences between samples
were determined by Dunnett’s multiple comparison test,
usingtheGraphPadPrism(statistical)software.Resultswere
considered to be signiﬁcant at P ≤ 0.05.
3. Results
Table 1 results showed 100% live foetuses and 0% resorption
w i t ha v e r a g el i t t e rn u m b e ro f7 .33 ± 0.023 (group 1), 8.33 ±
0.43 (group 2), and 8.00 ± 0.00 (group 3).
There were signiﬁcant (P ≤ 0.05) reductions in the body
weight and placenta weight of animals that received thera-
peutic doses of combined ﬁxed-dose antituberculous agents
(group 2) and combined ﬁxed-dose antituberculous agents
plus vitamin C (group 3) compared with the control group
(Table2).Thecrownrumplength,umbilicalcordlength,and
taillengthshowednosigniﬁcant(P ≥ 0.05),diﬀerenceacross
groups.Thegrosspathology(morphology)resultsofthefoe-
tuses of treated animals revealed no abnormalities (Table 3).
There were signiﬁcant (P ≤ 0.05) reductions in the plat-
elet counts between the pups of animals that received thera-
peutic doses of combined ﬁxed-dose antituberculous agents
(group 2) and combined ﬁxed-dose antituberculous agents
plus vitamin C (group 3) compared with the control group.
The neutrophiles results of group 2 (0.8100 ± 0.1643) signif-
icantly reduced compared with the control group and com-4 The Scientiﬁc World Journal
Table 3: Gross pathological (morphology) results of fetuses of treated animals.
Groups Stage of
exposure
No. of
foetus use
Formation of
digital rays
Neural
tube defect
Cleft
palate
General growth
abnormalities
Abnormal
heart
Abnormal
liver
Abnormal
brain
Abnormal
kidney
Group 1 ORG 18 0/18 0/18 0/18 0/18 0/18 0/18 0/18 0/18
Group 2 ORG 18 0/18 0/18 0/18 0/18 0/18 0/18 0/18 0/18
Group 3 ORG 18 0/18 0/18 0/18 2/18 0/18 0/18 0/18 0/18
ORG: organogenesis.
Group 1: control group. Group 2: administered with clinical dose (51.4mg/kg/day) of ﬁxed-dose combined antituberculous agents. Group 3: administered
with clinical dose of ﬁxed-dose combined antituberculous agents plus 10mg/kg/day of Vitamin C.
Table 4: Hematological Proﬁle of Rats at ﬁrst ﬁlial.
Groups SOE NOF WBC
(Mean±SEM)
RBC
(Mean±SEM)
HGB
(Mean±SEM)
HCT
(Mean±SEM)
PCT
(Mean±SEM)
LYPM
(Mean± SEM)
NEU
(Mean±SEM)
Group 1 ORG 6 5.433 ±0.2319 6.677 ±0.1444 13.70 ±0.2646 40.92 ±0.6519 792.5 ±18.92 3.705 ±0.2207 1.345 ±0.1276
Group 2 ORG 6 4.983 ±1.101 6.330 ±0.2752 11.97 ±0.7864 38.83 ±1.456 372.7 ±72.42
∗ 3.722 ±0.8835 0.8100 ±0.1643
∗
Group 3 ORG 6 6.517 ±0.7510 6.108 ±0.3862 11.98 ±0.695 37.17 ±1.615 475.7 ±100.7
∗ 4.717 ±0.4642 1.622 ±0.2774
SOE: stage of exposure, NOF: number of animals, ORG: organogenesis, WBC: white blood cell count, RBC: red blood cell count, HGB: hemoglobin count,
HCT: haematocrit, PCT: platelet count, LYPM: lymphocyte, NEU: neutrophiles.
∗P ≤ 0.05 compared with group 1 (control).
Group 1: control group. Group 2: administered with clinical dose (51.4mg/kg/day) of ﬁxed-dose combined antituberculous agents. Group 3: administered
with clinical dose of ﬁxed-dose combined antituberculous agents plus 10mg/kg/day of Vitamin C.
bined ﬁxed-dose antituberculous agents plus vitamin C
(group3).Therewerenosigniﬁcantdiﬀerences(P ≥ 0.05)in
thewhitebloodcells,redbloodcells,haematocrit,andhaem-
oglobin results across the groups (Table 4).
Table 5 shows a signiﬁcant increase (P ≤ 0.05) in
the values of AST (213.3 ± 16.35) of the pups of animals
that received therapeutic doses of combined ﬁxed-dose
antituberculous agents (group 2) compared with control
group (151.3 ± 12.25). There was a subsequent reduction
(P ≤ 0.05) in the AST value of animals that received
combined ﬁxed-doses antituberculous agents plus vitamin C
compared with group 2. A signiﬁcant increase was observed
in the urea levels of the pups of animals that received
therapeutic doses of combined ﬁxed-dose antituberculous
agents (group 2) and combined ﬁxed-dose antituberculous
agents plus vitamin C (group 3) compared with the control
group. There was also a signiﬁcant decrease in the level of
total protein of the pups of animals that received therapeutic
doses of combined ﬁxed-dose antituberculous agents and
combined ﬁxed-dose antituberculous agents plus vitamin C
compared with the control group. The pups of the animals
that received therapeutic doses of combined ﬁxed-dose
antituberculous agents showed an elevated level of ALP
compared with the control group (171.9 ± 3.65). However,
there was a remarkable increase (P ≤ 0.05) in the ALP
level of the pups of animals that received combined ﬁxed-
dose antituberculous agents plus vitamin C (287 ± 55.3)
compared with the pups of animals that received combined
ﬁxed-dose antituberculous agents (211.6 ±12.9).
Figure 1 showed the histology slides of the liver cells.
There were focal areas of hepatocyte necrosis seen in the
group treated with ﬁxed-dose combined antituberculous
agents(1b)andhepatocyteswithintracytoplasmicinclusions
in the group treated with ﬁxed-dose combined antituber-
culous agents plus vitamin C (1c). There was acute tubular
necrosis seen in the kidney cells of both the group treated
with the ﬁxed-dose combined antituberculous agents (2b)
and that treated with ﬁxed dose combined antituberculous
agents plus vitamin C (2c) (Figure 2).
4. Discussion
It is a general principle that the administration of any drug
to a pregnant patient is to be avoided, because of possible
fetaldamage. However, the treatmentof TB in pregnancy has
beenadvocated;giventhatthebeneﬁtoftreatmentlikelyout-
weighs the risk of fetal damage, even in the case of drugs that
mayhavesometoxicityassociatedwithinuteroexposure[6].
In the last decade, the conventional single-drug preparations
used in the management of TB have been replaced by ﬁxed-
dose combination (FDC) therapy [8]. The studies of Tasduq
et al. [21] and Awodele et al. [22] have documented the
hepatotoxicity of isoniazid and rifampicin. However, there
is little and controversial data on the teratogenicity of ﬁxed-
dose combined antituberculous agents.
The present study showed that ﬁxed-dose combined
antituberculous agents had no eﬀect on the morphology
(physical appearance) of the foetuses. However, there was a
signiﬁcantly low birth weight of the foetuses of the animals
that were treated with ﬁxed-dose combined antituberculous
agents. This observation may infer that children born from
mothers that have undergone tuberculosis treatment dur-
ing pregnancy using ﬁxed-dose combined antituberculous
agents have the tendency of having stunted growth, slow
cognitive development, and chronic disease later in life [23].
Studies have also proposed that children with low birth
weight have an increased risk of developing diabetes [24, 25],
obesity [26], and reduced intelligence [27] later in life.The Scientiﬁc World Journal 5
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Figure 1: (a) The micrograph of the liver section obtained from
ﬁrstﬁlialcontrolrats,magniﬁcation ×400.(A)Hepaticcentralvein,
(B) normal hepatocyte. (b) The micrograph of the liver section
obtained from ﬁrst ﬁlial rats treated with ﬁxed-dose combined
antituberculous agents, magniﬁcation ×400. (A) Hepatic necrosis,
(B) hepatic central vein. (c) The micrograph of the liver section
obtained from ﬁrst ﬁlial rats treated with ﬁxed-dose combined
antituberculous agents plus vitamin C, mag ×40. (A) Hepatocytes
with intracytoplasmic inclusions, (B) hepatic central veins.
The haematological parameters revealed a reduction in
the platelets counts and neutrophiles of the animals treated
with antituberculous agents at the ﬁrst ﬁlial generation. The
low neutrophiles and platelets may indicate that the use of
ﬁxed-dose antituberculous agents in pregnancy could result
in immune suppression and bleeding disorder of the fetuses,
respectively. There were also signiﬁcant (P ≤ 0.05)
elevations in the levels of aspartate aminotransferase (AST)
and alkaline phosphatase (ALP) in the fetuses of the animals
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Figure 2: (a) The micrograph of the kidney section obtained from
ﬁrstﬁlial control rats,magniﬁcation ×400. (A) Normal glomerulus.
(b) The micrograph of the kidney section obtained from ﬁrst
ﬁlial rats treated with ﬁxed-dose combined antituberculous agents,
mag ×40. (A) Acute tubular necrosis. (c) The micrograph of the
kidney section obtained from ﬁrst ﬁlial rats treated with ﬁxed-dose
combined antituberculous agents plus vit C, mag ×40. (A) Acute
tubular necrosis.
treated with ﬁxed-dose combined antituberculous agents.
These elevations may indicate liver damage in the ﬁrst ﬁlial
generation [28, 29]. The pups of animals that were treated
with combination of vitamin C and ﬁxed-dose antitubercu-
lous agents showed a signiﬁcant reduction in the AST
level compared with the pups of animals that received only
antituberculous agents. This result may underscore the mod-
ulatory ability of vitamin C against the ﬁxed-dose com-
bined antituberculous agents eﬀect on inducing hepaticThe Scientiﬁc World Journal 7
damage, and it corroborates the earlier ﬁnding of Awodele
et al. [22]. The histopathological examination of the hepatic
cells corroborated the liver enzymes results. There were
focal areas of hepatocyte necrosis seen in the ﬁxed-dose-
combined-antituberculous-treated group, however, only
hepatocytes with intracytoplasmic inclusions were seen in
the group treated with ﬁxed-dose antituberculous agents
plusvitaminC.Thehistologyofthekidneycellsalsorevealed
acute tubular necrosis in both the group treated with ﬁxed-
dose combined antituberculous agents and that treated with
ﬁxed-dose combined antituberculous agents plus vitamin
C. Although the blood chemistry results did not show a
signiﬁcant diﬀerence (P ≤ 0.05) in the level of creatinine of
the group treated with ﬁxed-dose combined antituberculous
agents compared with control, a signiﬁcant elevation in the
level of urea of the group treated with ﬁxed-dose combined
antituberculous agents was observed; the clinical correlation
of these results may indicate renal injury.
5. Conclusion
Fixed dose combined antituberculous agents have terato-
genic potential as shown in low birth weight, mild liver and
kidney damage in the ﬁrst ﬁlial of the treated animals. As
much as it is imminent to treat TB patients in pregnancy,
there is need to always exercise caution and clinically weigh
the risk-beneﬁts ratio. Options of induced abortion may be
considered in patients with TB during pregnancy in order to
avoid unwanted congenital malformations.
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